These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 35535695)

  • 1. Serum parameters as prognostic biomarkers in a real world cancer patient population treated with anti PD-1/PD-L1 therapy.
    Minichsdorfer C; Gleiss A; Aretin MB; Schmidinger M; Fuereder T
    Ann Med; 2022 Dec; 54(1):1339-1349. PubMed ID: 35535695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pretreatment Glasgow prognostic score predicts survival among patients with high PD-L1 expression administered first-line pembrolizumab monotherapy for non-small cell lung cancer.
    Imai H; Kishikawa T; Minemura H; Yamada Y; Ibe T; Yamaguchi O; Mouri A; Hamamoto Y; Kanazawa K; Kasai T; Kaira K; Kaburagi T; Minato K; Kobayashi K; Kagamu H
    Cancer Med; 2021 Oct; 10(20):6971-6984. PubMed ID: 34414673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gustave Roussy Immune Score and Royal Marsden Hospital Prognostic Score Are Biomarkers of Immune-Checkpoint Inhibitor for Non-Small Cell Lung Cancer.
    Minami S; Ihara S; Ikuta S; Komuta K
    World J Oncol; 2019 Apr; 10(2):90-100. PubMed ID: 31068989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer.
    Mezquita L; Auclin E; Ferrara R; Charrier M; Remon J; Planchard D; Ponce S; Ares LP; Leroy L; Audigier-Valette C; Felip E; Zerón-Medina J; Garrido P; Brosseau S; Zalcman G; Mazieres J; Caramela C; Lahmar J; Adam J; Chaput N; Soria JC; Besse B
    JAMA Oncol; 2018 Mar; 4(3):351-357. PubMed ID: 29327044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A systematic review and meta-analysis of prognostic indicators in patients with head and neck malignancy treated with immune checkpoint inhibitors.
    Kang D; Liu S; Yuan X; Liu S; Zhang Z; He Z; Yin X; Mao H
    J Cancer Res Clin Oncol; 2023 Dec; 149(20):18215-18240. PubMed ID: 38078963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gustave Roussy Immune Score Is a Prognostic Factor for Chemotherapy-Naive Pulmonary Adenocarcinoma With Wild-Type Epidermal Growth Factor Receptor.
    Minami S; Ihara S; Komuta K
    World J Oncol; 2019 Feb; 10(1):55-61. PubMed ID: 30834052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prognostic and predictive roles of plasma C-reactive protein and PD-L1 in non-small cell lung cancer.
    Kuusisalo S; Tikkanen A; Lappi-Blanco E; Väisänen T; Knuuttila A; Tiainen S; Ahvonen J; Iivanainen S; Koivunen JP
    Cancer Med; 2023 Aug; 12(15):16087-16097. PubMed ID: 37329173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and Validation of a Prognostic Score for Hepatocellular Carcinoma Patients in Immune Checkpoint Inhibitors Therapies: The Hepatocellular Carcinoma Modified Gustave Roussy Immune Score.
    Li Y; Pan Y; Lin X; Hou J; Hu Z; Xu L; Zhou Z; Zhang Y; Chen M; Hu D
    Front Pharmacol; 2021; 12():819985. PubMed ID: 35237150
    [No Abstract]   [Full Text] [Related]  

  • 9. The Gustave Roussy Immune (GRIm)-Score Variation Is an Early-on-Treatment Biomarker of Outcome in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Pembrolizumab.
    Lenci E; Cantini L; Pecci F; Cognigni V; Agostinelli V; Mentrasti G; Lupi A; Ranallo N; Paoloni F; Rinaldi S; Nicolardi L; Caglio A; Aerts S; Cortellini A; Ficorella C; Chiari R; Di Maio M; Dingemans AC; Aerts JGJV; Berardi R
    J Clin Med; 2021 Mar; 10(5):. PubMed ID: 33801320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score).
    Bigot F; Castanon E; Baldini C; Hollebecque A; Carmona A; Postel-Vinay S; Angevin E; Armand JP; Ribrag V; Aspeslagh S; Varga A; Bahleda R; Menis J; Gazzah A; Michot JM; Marabelle A; Soria JC; Massard C
    Eur J Cancer; 2017 Oct; 84():212-218. PubMed ID: 28826074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of the Advanced Lung Cancer Inflammation Index (ALI) and Gustave Roussy Immune (GRIm) score with immune checkpoint inhibitor efficacy in patients with gastrointestinal and lung cancer.
    Jiang H; Li B; Wu M; Wang Q; Li Y
    BMC Cancer; 2024 Apr; 24(1):428. PubMed ID: 38589844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre- and on-treatment lactate dehydrogenase as a prognostic and predictive biomarker in advanced non-small cell lung cancer.
    Tjokrowidjaja A; Lord SJ; John T; Lewis CR; Kok PS; Marschner IC; Lee CK
    Cancer; 2022 Apr; 128(8):1574-1583. PubMed ID: 35090047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of programmed cell death-ligand 1 expression on circulating tumor cells in various cancers: A systematic review and meta-analysis.
    Ouyang Y; Liu W; Zhang N; Yang X; Li J; Long S
    Cancer Med; 2021 Oct; 10(20):7021-7039. PubMed ID: 34423578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients.
    Mazzaschi G; Minari R; Zecca A; Cavazzoni A; Ferri V; Mori C; Squadrilli A; Bordi P; Buti S; Bersanelli M; Leonetti A; Cosenza A; Ferri L; Rapacchi E; Missale G; Petronini PG; Quaini F; Tiseo M
    Lung Cancer; 2020 Oct; 148():1-11. PubMed ID: 32768804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gustave Roussy Immune Score and Royal Marsden Hospital Prognostic Score Are Prognostic Markers for Extensive Disease of Small Cell Lung Cancer.
    Minami S; Ihara S; Komuta K
    World J Oncol; 2020 Jun; 11(3):98-105. PubMed ID: 32494316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-World Outcomes of Patients With Advanced Non-small Cell Lung Cancer Treated With Anti-PD1 Therapy on the Basis of PD-L1 Results in EBUS-TBNA vs Histological Specimens.
    Tajarernmuang P; Ofiara L; Beaudoin S; Wang H; Benedetti A; Gonzalez AV
    Chest; 2021 Aug; 160(2):743-753. PubMed ID: 33675792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of pretreatment Glasgow prognostic score in stage IIIB geriatric non-small cell lung cancer patients undergoing radical chemoradiotherapy.
    Topkan E; Bolukbasi Y; Ozdemir Y; Besen AA; Mertsoylu H; Selek U
    J Geriatr Oncol; 2019 Jul; 10(4):567-572. PubMed ID: 31178158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Significance of Serum Biomarkers in Stage IV Non-Small-Cell Lung Cancer Treated with PD-1 Inhibitors: LIPI Score, NLR, dNLR, LMR, and PAB.
    Chen J; Wei S; Zhao T; Zhang X; Wang Y; Zhang X
    Dis Markers; 2022; 2022():7137357. PubMed ID: 35945957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
    Shoji F; Takeoka H; Kozuma Y; Toyokawa G; Yamazaki K; Ichiki M; Takeo S
    Lung Cancer; 2019 Oct; 136():45-51. PubMed ID: 31437663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer.
    Banna GL; Cortellini A; Cortinovis DL; Tiseo M; Aerts JGJV; Barbieri F; Giusti R; Bria E; Grossi F; Pizzutilo P; Berardi R; Morabito A; Genova C; Mazzoni F; Di Noia V; Signorelli D; Gelibter A; Macerelli M; Rastelli F; Chiari R; Rocco D; Gori S; De Tursi M; Di Marino P; Mansueto G; Zoratto F; Filetti M; Montrone M; Citarella F; Marco R; Cantini L; Nigro O; D'Argento E; Buti S; Minuti G; Landi L; Guaitoli G; Lo Russo G; De Toma A; Donisi C; Friedlaender A; De Giglio A; Metro G; Porzio G; Ficorella C; Addeo A
    ESMO Open; 2021 Apr; 6(2):100078. PubMed ID: 33735802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.